Pulmonary microecology is a key role of traditional Chinese medicine in improving pulmonary fibrosis  

作　　者：Ze-Hua Wang Zhi-Feng Xue 

机构地区：[1]Third Hospital of Shanxi Medical University,Shanxi Bethune Hospital,Shanxi Academic of Medical Science,Tongji Shanxi Hospital,Taiyuan 030032,China [2]Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China

出　　处：《TMR Integrative Medicine》2023年第28期1-2,共2页TMR整合医学

基　　金：financially supported by the Fundamental Research Program of Shanxi Province(202203021221238);Research Projects of Shanxi Provincial Administration of Traditional Chinese Medicine(2023ZYYB027).

摘　　要：Idiopathic pulmonary fibrosis(IPF)is a type of interstitial lung disease,characterized by an unknown etiology,chronicity,and progressive respiratory impairment.Following IPF diagnosis,patients exhibit a median survival of only 2 to 3 years,with a staggering 70% to 80% mortality rate within 5 years[1].However,the corresponding therapeutic options remain severely limited.Presently,the efficacious treatment drugs are Pirfenidone and Nintedanib.Regrettably,these two drugs fail to substantially reverse pulmonary fibrosis,offering only a partial slowing of its progression.IPF predominantly afflicts the elderly[1],and with the aging population in China constinuously increasing,there is a compelling need to explore novel and more effective treatment strategies.

关 键 词：DRUGS DIAGNOSIS treatment 

分 类 号：R259[医药卫生—中西医结合]